Brought to you by 
Galenica Group buys Aspreva for $915mm
23 Oct 2007
Executive Summary
Switzerland's Galenica Group (manufactures and sells nephrology drugs, runs pharmacies, and has a logistics/health care information business) has agreed to pay $915mm in cash ($26 per share; a 19% premium) to acquire Aspreva (autoimmune disease therapeutics).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galenica Group buys Aspreva for $915mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice